BS_45J79YTF
high-grade glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- high-grade glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- high-grade glioma
- overall_survival_months
- 7.293035479632063
- age_years
- 4.986
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.601
- G2M_CHECKPOINT+0.582
- MYC_TARGETS_V1+0.402
- MYC_TARGETS_V2+0.349
- MITOTIC_SPINDLE+0.303
- PANCREAS_BETA_CELLS+0.255
- DNA_REPAIR+0.125
- SPERMATOGENESIS+0.118
- UNFOLDED_PROTEIN_RESPONSE+0.085
- WNT_BETA_CATENIN_SIGNALING+0.009
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.509
- INTERFERON_GAMMA_RESPONSE-0.467
- TNFA_SIGNALING_VIA_NFKB-0.427
- ALLOGRAFT_REJECTION-0.410
- IL6_JAK_STAT3_SIGNALING-0.397
- APOPTOSIS-0.394
- BILE_ACID_METABOLISM-0.393
- INFLAMMATORY_RESPONSE-0.384
- TGF_BETA_SIGNALING-0.383
- ANGIOGENESIS-0.356
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
0 twins match this tumor's tissue · 10 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_3F5PR9GS | medulloblastoma | — | 0.967 |
| 2 | BS_AM70R8RG | medulloblastoma | — | 0.964 |
| 3 | BS_BVSW4GTG | medulloblastoma | — | 0.961 |
| 4 | BS_FCAKKZ20 | medulloblastoma | — | 0.960 |
| 5 | BS_7XQRH69M | medulloblastoma | — | 0.959 |
| 6 | BS_W644VEVE | medulloblastoma | — | 0.958 |
| 7 | BS_09Z7TC35 | medulloblastoma | — | 0.954 |
| 8 | BS_FBJ5Q54N | Embryonal tumors | — | 0.952 |
| 9 | BS_7C40TRCY | medulloblastoma | — | 0.950 |
| 10 | BS_TYAYZ9ZW | medulloblastoma | — | 0.950 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 10 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.601 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.582 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.402 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.349 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.303 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.255 | Cobimetinib | — uncovered |
| DNA_REPAIR | 0.125 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.118 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.085 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.009 | Inavolisib | — uncovered |